Right as Rain: Invisible Illnesses - Chapelboro.com

This week I got back from another round of video shoots for my client, the Carcinoid Cancer Foundation. They help raise awareness, educate people, and connect patients of neuroendocrine and carcinoid tumors to specialists around the world. 

It’s an incredible community of people bound together to learn more and better manage this rare disease for patients and their caregivers. I am proud to be a part of that community

Neuroendocrine cancer is often misdiagnosed since symptoms reflect those of other gut-related and less-threatening diseases.  This makes it difficult for patients to pursue the right treatment and they can even go years without being properly diagnosed.  

Another thing that makes it complicated for patients (and for doctors to diagnose) is that it’s an invisible illness.

They “don’t look like cancer patients,” in other words. 

Continue reading
  36 Hits

Copyright

© news.google.com

36 Hits

Multiple Doses of Stem Cells Show Potential in Treating Severe Asthma - Yahoo Finance

Researchers at the Federal University of Rio de Janeiro and the National Institute of Science and Technology for Regenerative Medicine describe how multiple doses of a type of stem cell called mesenchymal stromal cells (MSCs) might offer a new way to treat people suffering from severe asthma. Results were reported in STEM CELLS Translational Medicine.

DURHAM, N.C., Nov. 20, 2019 /PRNewswire-PRWeb/ -- A study released today in STEM CELLS Translational Medicine (SCTM) describes how multiple doses of a type of stem cell called mesenchymal stromal cells (MSCs) might offer a new way to treat people suffering from severe asthma.

An asthma attack is triggered by allergens entering the lungs and causing swelling of the airways. This sets off a domino effect that results in narrowing of the airways from the nose and mouth to the lungs. The most severe cases can lead to death. According to the Centers for disease Control and Prevention, one in 13 people have asthma. There is no cure, but it can be managed in most cases with proper prevention and treatment.

The study in SCTM, conducted by researchers at the Federal University of Rio de Janeiro and the National Institute of Science and Technology for Regenerative Medicine, focused on a new treatment for asthma brought on by house dust mites (HDMs). Some estimate that these common microscopic creatures are the culprit behind nearly 85 percent of all asthma attacks.

Patricia Rieken Macedo Rocco, M.D., Ph.D., was lead investigator on the study. "Previous experiments tell us that a single dose of adipose tissue-derived MSCs reduced lung inflammation in asthma brought on by HDMs, but it was unable to reverse lung remodeling," she said. "We wanted to see how multiple doses of MSCs might perform."

Continue reading
  37 Hits

Copyright

© news.google.com

37 Hits

With Bristol-Myers CVR, Investors Can Bet on 3 Drugs in Celgene’s Pipeline - Barron's

An intriguing and appealing new security begins trading on the New York Stock Exchange on Thursday. It amounts to a bet that three drugs in Celgene’s pipeline will gain regulatory approval by the end of the first quarter of 2021.

The CVRs are being issued as a bonus to Celgene shareholders by Bristol-Myers to compensate them if major drugs in the Celgene pipeline get approved and Bristol-Myers derives significant financial benefit.

The CVR was changing hands on Wednesday morning under the ticker BQBBV at $2.23, up 35.5 cents on the session. It is expected to switch to a different ticker, BMY-R, on the New York Stock Exchange starting on Thursday.

The security is attracting interest from drug investors, including many hedge funds, because it offers a large payoff of $9 in cash per right if all three drugs are approved by certain dates. The three drugs are each given a high chance of approval on Wall Street.

Still, the CVR amounts to an all or nothing bet. As one investor told Barron’s: “It’s a binary situation. The value will either be $9 or zero.”

Continue reading
  47 Hits

Copyright

© news.google.com

47 Hits

MS Is Making Me Lose My Grip - Everyday Health

Dropping things can be a consequence of weakness, numbness, or lack of coordination brought on by MS.

Andy Baker/Getty Images

How many times hasn’t a glass, a toothbrush, a pencil, or innumerable other objects jumped from my Multiple Sclerosis (MS)–affected hands when I try to grasp them with and for purpose? How many times have I reached for some aspect of life, formerly quite attainable by my pre-MS self, only to find it either out of my reach or — in the rare case when I can get hold of it — too onerous to hang on to?

It’s an ongoing lesson of this life with a progressive, debilitating neurological disease. The me of before — both physically and figuratively — has lost his grip.

My inability to attain, hold, and manipulate objects to my intention is due to progressive demyelination of the nerves in my central nervous system. It’s also caused by the weakening of muscles that receive signals from those nerves over time. My fine motor skills make it difficult to get things, and my loss of strength makes it difficult hold onto and do anything useful with them.

Continue reading
  38 Hits

Copyright

© news.google.com

38 Hits

Global Primary Progressive Multiple Sclerosis Treatment Market 2019 – F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc. - Industry Report 24

The Primary Progressive Multiple Sclerosis Treatment report delivers a comprehensive and systematic framework of the worldwide Primary Progressive Multiple Sclerosis Treatment Market at a global level that includes all the key aspects related to it. The data is collected from different sources allied to the Primary Progressive Multiple Sclerosis Treatment and the research team meticulously analyze the gathered data with the help of various analytically tools and present their opinion based on analysis and calculations.

The Global Primary Progressive Multiple Sclerosis Treatment Market 2019 report offers clear-cut information about the key business-giants F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc., Kyorin Pharmaceutical Co., Ltd., MedDay SA, Santhera Pharmaceuticals Holding AG, Teva Pharmaceutical Industries Ltd. challenging with each other in the worldwide Primary Progressive Multiple Sclerosis Treatment in terms of demand, sales, revenue generation, reliable products development, giving best services, and also post-sale processes at the global level.

To Get Free Sample Copy of Report Click Here: http://www.mrsresearchgroup.com/report/170384#request-sample

This Global Primary Progressive Multiple Sclerosis Treatment Market 2019 report is integrated with primary as well as secondary research of the Global industry. The worldwide Primary Progressive Multiple Sclerosis Treatment in detail and presents comprehensive forecasts regarding the market’s growth trajectory during the forecast period (2019 – 2025)

The Global Primary Progressive Multiple Sclerosis Treatment Market 2019 report is based on key players, which are combined by market share, history of growth and Industry forecasts, it provides in-detailed information, basic needs of the market, and the report shows the how this market is growing Globally. The main regions that contribute to the worldwide Primary Progressive Multiple Sclerosis Treatment Market 2019 are United States, Europe, Japan, China, India, Southeast Asia.

Continue reading
  45 Hits

Copyright

© news.google.com

45 Hits

How an MRI to Confirm I Have MS May Have Saved My Life - Yahoo Lifestyle

“Wait, what? Can you spell that?” I asked. 

“M-E-N-I-N-G-I-O-M-A,” the doctor replied. 

“What is that?” I asked him, quite confused.

***

It started one winter day back in 1996. We all got up for school — my kids for a regular day and me to help at the school’s “Be Into Geography” program. I loved helping at school. This day was different though. I felt funny. My fingers were numb. And when I was walking, I couldn’t feel my feet hitting the ground. Kinda like walking on pillows. Such a strange sensation. At school, the other parents said, “Maybe you’re coming down with something… maybe the cold temperature has something to do with it…” Who knows?

Continue reading
  17 Hits

Copyright

© news.google.com

17 Hits

Ocean swim challenge shines spotlight on Crystal Pool plight - Victoria News

A Victoria marathon swimmer has challenged Victoria councillors to a long-distance swim in the ocean so they can “experience what it will be like for ordinary Victorians to swim if Crystal Pool shuts down.”

Susan Simmons, known for a number of open water swims in Greater Victoria and for overcoming Multiple Sclerosis (MS) to achieve ultra-marathon swim achievements, has made her position on Crystal Pool crystal clear.

RELATED: Victoria city staff start from square one on Crystal Pool project

She has made a tongue-in-cheek request to councillors to join her Dec. 1 and take a dip in the ocean at Ogden Point to experience swimming without a community pool.

“Replacing this vital community pool – used mainly by ordinary members of the community – is once again at a standstill as council debates – again – the design of the pool,” says Simmons in a statement. “”At this rate, there will be another election before anything is decided, and we’ll be without a community swimming facility well beyond 2024 – if it ever gets built.”

Continue reading
  18 Hits

Copyright

© news.google.com

18 Hits

EMA committee recommends caution in use of tofacitinib owing to increased risk of blood clots - The Pharmaceutical Journal

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has endorsed recommendations that tofacitinib (Xeljanz; Pfizer) could increase the risk of blood clots in the lungs and should be used with caution in all patients already at high risk.

Tofacitinib is indicated for moderate-to-severe active rheumatoid arthritis (RA) in patients who have had an inadequate response to, or are intolerant to one or more disease-modifying anti-rheumatic medicines, as well as psoriatic arthritis and severe ulcerative colitis (UC).

The EMA has said that maintenance doses of 10mg twice daily should not be used in patients with UC who are at high risk of blood clots, unless there is no suitable alternative treatment. It also recommended that, owing to an increased risk of infection, patients aged over 65 years should only be treated with tofacitinib when there is no alternative treatment.

These recommendations follow a review of an ongoing study in patients with RA and an increased risk of cardiovascular disease, along with data from earlier studies and consultations with experts in the field.

At its meeting, held on 11–14 November 2019, the CHMP also endorsed recommendations to restrict the use of Multiple Sclerosis (MS) medicine alemtuzumab (Lemtrada; Genzyme) owing to reports of rare but serious side effects, including cardiovascular and immune-related disorders and deaths.

Continue reading
  23 Hits

Copyright

© news.google.com

23 Hits

Leading Suicide Prevention Organization and Correctional Health Care Experts Release Suicide Prevention Resource Guide - P&T Community

NEW YORK, Nov. 20, 2019 /PRNewswire/ -- According to the U.S. Department of Justice, suicide is the leading cause of death in jails, and the suicide rate in prisons continues to increase. The National Commission on Correctional Health Care (NCCHC) and the American Foundation for Suicide Prevention (AFSP) have created an authoritative resource on preventing suicide in correctional facilities, the Suicide Prevention Resource Guide. This guide is free and available to the public.

Drawing from both organizations' expertise, with input from national experts in the field of correctional mental health and suicide prevention, this guide provides a road map, tools and resources for navigating the complexities of suicide prevention within correctional facilities – a serious problem in the United States.

"Research tells us that people in times of transition are at especially high risk for suicide, and incarcerated people are particularly vulnerable due to health and situational reasons," said Robert Gebbia, CEO of AFSP.

The nation's largest suicide prevention organization, AFSP, joined NCCHC's ongoing efforts to reduce suicide among incarcerated populations as part of its Project 2025, which aims to reduce the annual suicide rate 20 percent by 2025. AFSP identified the correctional system as one of four critical areas where evidence points to saving the most lives in the shortest amount of time.

The Suicide Prevention Resource Guide focuses on three key areas, with the goal to educate people who work in jails and prisons on how to better identify and help inmates at risk for suicide, safely manage those identified as high risk, and provide consistent, comprehensive training to all involved personnel.

Continue reading
  33 Hits

Copyright

© news.google.com

33 Hits

Frank Stitt honored with Rotary Trail sculpture - Birmingham Business Journal

Frank Stitt honored with Rotary Trail sculpture  Birmingham Business Journal
  17 Hits

Copyright

© news.google.com

17 Hits

Dennis Lee Johnson -- Rochester - PostBulletin.com

Dennis L. Johnson, 80, of Rochester, died on Nov. 12, 2019 at Saint Marys Hospital in Rochester. He was born to Tony and Ida Johnson on Nov. 10, 1939, in Tracy, Minn. He graduated from Walnut Grove High School in 1957 and the University of Minnesota in 1961. He married Joann Monson in August 1969, in Marine on St. Croix. 

Dennis spent most of his adult life living with Multiple Sclerosis. He became an inspiration to many because of his positive attitude, great smile, and determination to keep doing the things he loved. He taught in Farmington, Pine Island and Rochester. He was a volunteer track coach at Mayo High School for 21 years and made many lasting relationships with members of the team as he coached from his mobility scooter. He spent many summers working with the All Comer Track Meets in Rochester. Dennis was also a member of the Eagles Aerie 2228 Rochester.

He is survived by his wife, Joann; brother, Donald of Walnut Grove; brother, Doug (Sharon) of Spring Hill, Fla.; sister, Evonne Phillippe (Gene) of Surprise Ariz.; many nieces and nephews; and some great-nieces and nephews. He is preceded in death by his parents and sister-in-law, Judy Johnson.

Dennis enjoyed trap shooting, University of Minnesota wrestling and cheering for and helping young athletes. He was a member of the Rochester Quarterbacks Club and the Dodge Center Sportsman's Club and the Southern Minnesota Sportsman's Club.

The funeral service for Dennis will be held 11 a.m. Nov. 19 at Macken Funeral Home in Rochester with Pastors Paul Hauschild and Ron Hackmann officiating. A visitation will be from 4 p.m. to 7 p.m. Monday, Nov. 18 at Macken Funeral Home and one hour prior to the service on Tuesday. Burial will be in Oakwood Cemetery in Rochester.

Continue reading
  50 Hits

Copyright

© news.google.com

50 Hits

EMA/CHMP backs five novel medicines for approval - The Pharma Letter

EMA/CHMP backs five novel medicines for approval  The Pharma Letter
  45 Hits

Copyright

© news.google.com

45 Hits

Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active Secondary Progressive Multiple Sclerosis (SPMS)

DetailsHits: 158If approved, Mayzent® (siponimod) will be the first and only oral treatment specifically indicated for patients with active Secondary Progressive Multiple Sclerosis (SPMS) in Europe[1])CHMP opinion is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad SPMS patient population (EDSS score 3.0 to 6.5 at baseline), showing Mayzent significantly reduced the risk of disease progression, including physical disability and cognitive decline[2]Up to 80% of patients with Relapsing Remitting Multiple Sclerosis (RRMS) will develop SPMS[3]; if approved, Mayzent would be a viable treatment option for those patients with active SPMS

BASEL, Switzerland I November 15, 2019 I Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Mayzent® (siponimod) for the treatment of adult patients with Secondary Progressive Multiple Sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity (i.e. Gd-enhancing T1 lesions or active, new or enlarging, T2 lesions). While MS progression is different for each patient and influenced by multiple factors, including use of MS disease-modifying treatments, it is estimated that up to 80% of patients will eventually transition from RRMS to SPMS [3]. If approved, Mayzent is expected to be the first and only oral treatment specifically indicated for patients with active SPMS based on a randomized clinical trial of a broad SPMS patient population.

“Today’s CHMP opinion marks a milestone in supporting people in Europe who are living with active SPMS,” said Christoph Thalheim, Director External Affairs, European Multiple Sclerosis Platform. “This decision brings hope of a possible new and beneficial therapy.”

The positive CHMP opinion for Mayzent is based on groundbreaking data from the Phase III EXPAND study, a randomized, double-blind, placebo-controlled trial, comparing the efficacy and safety of Mayzent versus placebo in people with SPMS. EXPAND also investigated a subgroup of patients with active disease (n=779), defined as patients with relapses in the two years prior to the study and/or presence of Gd-enhancing T1 lesions at baseline. The baseline characteristics were similar except for signs of activity compared to the overall population. Results from EXPAND in the overall population showed that Mayzent significantly reduced the risk of three-month confirmed disability progression (CDP) (primary endpoint; 21% reduction versus placebo, p=0.013) and meaningfully delayed the risk of six-month CDP (26% versus placebo, p=0.0058) [2]. 

In the subgroup of Mayzent-treated patients with active disease, results showed:

Time to onset of three‑month and six‑month CDP was significantly delayed by 31% compared to placebo and by 37% compared to placebo, respectively [4].The annualized relapse rate (ARR – confirmed relapses) was reduced by 46% compared to placebo [4].Significant favorable outcomes in other relevant measures of MS disease activity, including MRI disease activity and brain volume loss (brain shrinkage) [4].

Additional analyses of the EXPAND study were presented this year at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), demonstrating that Mayzent:

Continue reading
  66 Hits

Copyright

© news.google.com

66 Hits

Overcoming obstacles earns SUNY Oswego freshman statewide scholarship - NNY360

Buy Now

SUNY Oswego freshman Samia Montgomery’s resilience and achievements resulted in her becoming one of five statewide recipients of the Carey Gabay Scholarship Program.

Johnson Newspapers 7.1

Latest News

Most Popular

Classifieds

  41 Hits

Copyright

© news.google.com

41 Hits

Havana's 500th Anniversary a missed opportunity to strengthen U.S.-Cuba ties - New York Daily News

Havana's 500th Anniversary a missed opportunity to strengthen U.S.-Cuba ties  New York Daily News
  35 Hits

Copyright

© news.google.com

35 Hits

Brenda Joyce Peterson | Obituaries - Standard-Examiner

Please log in, or sign up for a new account to continue reading.

Continue reading
  26 Hits

Copyright

© news.google.com

26 Hits

Carisma Therapeutics Announces Investor Conference Participation - P&T Community

PHILADELPHIA, Nov. 16, 2019 /PRNewswire/ -- Carisma Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies based on engineered macrophages, today announced that it will be participating in three upcoming investor conferences.

Stifel 2019 Healthcare Conference, November 19-20, 2019 – Carisma's management will deliver a presentation on Wednesday, November 20, at 4:45 pm EDT and host one-on-one meetings at the venue. The conference will be held at the Lotte New York Palace Hotel, New York, NY.Jefferies 2019 London Healthcare Conference, November 20-21, 2019 – Carisma will host one-on-one meetings on November 20 and 21 at the conference venue, at the Waldorf Hilton, London, UK.Piper Jaffray 31st Annual Healthcare Conference, December 3-5, 2019 – Carisma's management team will present on Tuesday, December 3, at 4:50 pm EDT. The company will host one-on-one meetings at the conference venue, at the Lotte New York Palace Hotel in New York, NY.

Carisma Therapeutics is pioneering the development of engineered macrophages to transform the treatment of cancer and other serious illnesses through the engagement of both the innate and adaptive immune responses. Carisma's proprietary chimeric antigen receptor (CAR)-macrophage cell therapy platform is designed to address key challenges involved in the treatment of solid tumors by actively trafficking to the tumor, selectively killing tumor cells through phagocytosis, "warming up" the tumor microenvironment, and triggering a durable response from other immune cells.

Carisma's first product in development is an autologous HER2-targeted CAR-macrophage expected to enter clinical studies in 2020. Additional CAR-macrophages targeting other solid tumor antigens are in early development.

About Carisma Therapeutics Inc.

Carisma Therapeutics Inc. is a biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune responses. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma Therapeutics is headquartered in Philadelphia, PA.

Continue reading
  26 Hits

Copyright

© news.google.com

26 Hits

Multiple Sclerosis Drugs Market 2019| Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2026 | Research Industry US - News Obtain

Global Multiple Sclerosis Drugs Market presents insights on the current and future industry trends, enabling the readers to identify the product and services, hence driving the revenue growth and profitability. The research report provides a detailed analysis of all the major factors impacting the market on a global and regional scale, including drivers, constraints, threats, challenges, opportunities, and industry-specific trends. Further, the report cites global certainties and endorsements along with downstream and upstream analysis of leading players.

The Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis of Multiple Sclerosis Drugs Market. This research is conducted to understand the current landscape of the market, especially in 2018. This will shape the future of the market and foresee the extent of competition in the market. This report will also help all the manufacturers and investors to have a better understanding of the direction in which the market is headed.

Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority): http://researchindustry.us/report/multiple-sclerosis-drugs-market-ric/851565/request-sample

Competitive Landscape:

The Multiple Sclerosis Drugs Industry is severely competitive and fragmented due to the existence of various established players taking part in different marketing strategies to increase their market share. The vendors operating in the market are profiled based on price, quality, brand, product differentiation, and product portfolio. The vendors are turning their focus increasingly on product customization through customer interaction.

Continue reading
  41 Hits

Copyright

© news.google.com

41 Hits

Community news Saturday Nov. 16 - The San Diego Union-Tribune

CARLSBAD

Class registration offered at senior center

The Carlsbad Senior Center is presenting a free registration workshop for classes held at the Carlsbad Senior Center and at Pine Avenue Community Center from 10 to 11 a.m. on Tuesday, Nov. 19 at 3209 Harding St. Attendees will learn to create and edit an account online at CarlsbadConnect.org and how to locate and register online for City of Carlsbad classes. Call (760) 602-4650.

Flu shots given at senior center

The Carlsbad Senior Center will host licensed CVS Immunizing Pharmacists to administer the 2019 “All-in-one Influenza Vaccine” (Influenza A, Influenza B & H1N1) from 9 a.m. to 1 p.m. on Tuesday, Nov. 19 at 799 Pine Ave. Bring your Medicare Part B card and CVS will take care of billing Medicare for you. No appointment necessary. Call (760) 602-4654.

Continue reading
  36 Hits

Copyright

© news.google.com

36 Hits

Neurology group updates vaccine recommendations for patients with MS - Pharmacy Today, American Pharmacists Association, pharmacist.com

“We reviewed all of the available evidence, and for people with MS, preventing infections through vaccine use is a key part of medical care,” said lead author Mauricio F. Farez, MD, MPH, of the FLENI Institution in Buenos Aires, Argentina, and a member of AAN, in a statement. “People with MS should feel safe and comfortable getting their recommended vaccinations.”

The updated guideline recommends that patients with MS follow all local vaccine standards, as stated by CDC, the World Health Organization, and other local regulatory bodies.

After performing a systematic review of current evidence, the expert panel found no evidence that MS increases the risk of acquiring vaccine-preventable infections or that vaccination increases MS exacerbation. Individuals with MS have at least the same risk of acquiring these infections as unvaccinated individuals without MS, and vaccination of patients with MS also contributes to herd immunity. As such, vaccination poses benefits at both an individual and population level.

Providers should recommend that patients with MS receive the influenza vaccine annually, unless a patient has known sensitivities or has had severe reactions to the vaccine. Providers should also keep in mind local disease risks when counseling individuals with MS about vaccination, as the prevalence of vaccine-preventable diseases varies by country and region.

In any case, it’s important for providers to discuss with patients the updated recommendations and current evidence for immunization in patients with MS.

Continue reading
  133 Hits

Copyright

© news.google.com

133 Hits
 
 

Follow Us on Twitter

Follow Us On Twitter - Image